Syndax Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Syndax Pharmaceuticals

28/02/2023 22:46

* Syndax Pharmaceuticals Inc  SNDX.OQ  reported a quarterly
adjusted loss of 62 cents​​ per share for the quarter ended in
December. The mean expectation of eight analysts for the quarter
was for a loss of 65 cents per share.
    * Reported revenue was zero​; analysts expected $375.00
thousand. 
    * Syndax Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 62 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Syndax Pharmaceuticals Inc shares had fallen by 3.9% this
quarter.
    * The company reported a quarterly loss of $39.19 million.
    * Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is $33.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 10:46 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.65          -0.62          Beat
 Sep. 30 2022      -0.63          -0.58          Beat
 Jun. 30 2022      -0.64          -0.62          Beat
 Mar. 31 2022      -0.63          -0.63          Met